<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413088</url>
  </required_header>
  <id_info>
    <org_study_id>ROV-BEM-2005-01</org_study_id>
    <nct_id>NCT00413088</nct_id>
  </id_info>
  <brief_title>Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly</brief_title>
  <official_title>Clinical Trial to Assess Bemiparin Pharmacokinetics at Therapeutic (115 IU/kg) and Prophylactic Doses (3500 IU) Administered Subcutaneously in Single or Multiple Doses in Renal Insufficiency and in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rovi Pharmaceuticals Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rovi Pharmaceuticals Laboratories</source>
  <brief_summary>
    <textblock>
      Open pharmacokinetic study with 5 parallel groups and two treatment phases (bemiparin 3,500&#xD;
      IU multiple dose and bemiparin 115 IU/kg single dose). The bemiparin pharmacokinetic profile&#xD;
      will be assessed by measuring its effects on the coagulation cascade. Plasma anti-Xa activity&#xD;
      (measured using chromogenic amidolytic assay) in IU per milliliter will be the primary&#xD;
      endpoint to assess the pharmacokinetic profile of bemiparin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetics of bemiparin administered subcutaneously once daily for 4 days at prophylactic doses (3500 IU) and at a single therapeutic dose (115 IU/kg), in renal insufficiency and in the elderly.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of bemiparin in all volunteers and patients.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Insufficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bemiparin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Non-elderly healthy volunteers (Group I):&#xD;
&#xD;
          -  Male or female subjects aged between 18 and 65 years&#xD;
&#xD;
          -  body weight, clinical history, physical examination, vital signs (systolic and&#xD;
             diastolic blood pressure, heart beat rate and body temperature), ECG and laboratory&#xD;
             tests (hemogram and biochemistry) within normal range&#xD;
&#xD;
          -  without evidence of significant organic or psychiatric illness&#xD;
&#xD;
          -  who have accepted to participate in the study and have signed the written informed&#xD;
             consent.&#xD;
&#xD;
        Patients with renal insufficiency (Groups II, III and IV):&#xD;
&#xD;
          -  Male or female subjects aged between 18 and 65 years, who will be assigned to one of&#xD;
             the following groups according to renal function:&#xD;
&#xD;
               -  Group II: mild renal insufficiency (creatinine clearance &gt; 50 to 80 ml/min);&#xD;
&#xD;
               -  Group III: Moderate renal insufficiency (creatinine clearance: 30 to 50 ml/min);&#xD;
&#xD;
               -  Group IV: Severe renal insufficiency (creatinine clearance &lt; 30 ml/min). The&#xD;
                  degree of renal insufficiency will be calculated on the basis of determination of&#xD;
                  creatinine clearance measuring total urinary output over a 24-h period and serum&#xD;
                  creatinine levels. Urine samples will be collected no more than 2 weeks before&#xD;
                  the first experimental period.&#xD;
&#xD;
          -  Patients with renal insufficiency must have a stable renal function during the 3&#xD;
             months before their inclusion in the study.&#xD;
&#xD;
          -  They must have a body weight between 45 and 110 Kg.&#xD;
&#xD;
          -  They have to accept to participate in the study and have signed the written informed&#xD;
             consent.&#xD;
&#xD;
        Elderly healthy volunteers (Group V):&#xD;
&#xD;
          -  Male or female subjects aged &gt; 65 years old who fulfill with the remaining inclusion&#xD;
             criteria specified for non-elderly healthy volunteers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Non-elderly healthy volunteers (Group I):&#xD;
&#xD;
          -  Previous history of alcoholism or drugs consumption&#xD;
&#xD;
          -  Important consumer of exciting drinks&#xD;
&#xD;
          -  Hypersensitivity, allergy, idiosyncrasy to medicines&#xD;
&#xD;
          -  Taking another medication four weeks before the initiation of the trial including&#xD;
             medication without prescription and medicinal plants&#xD;
&#xD;
          -  Positive serology of hepatitis B, C or HIV virus&#xD;
&#xD;
          -  History or clinic evidence of concomitant disease&#xD;
&#xD;
          -  Familiar history of coagulation's disorders&#xD;
&#xD;
          -  surgery within the previous 6 months&#xD;
&#xD;
          -  Women who are pregnant or who are not using effective contra conceptive methods&#xD;
&#xD;
          -  Ethanol, cannabis, cocaine, amphetamine, benzodiazepin or opiate in urine&#xD;
&#xD;
          -  Current platelet count &lt; 100.000/mm3 or serum K &gt; 5,5 mEq/L&#xD;
&#xD;
          -  Any contraindication to bemiparin administration in order to authorized summary&#xD;
             product characteristics&#xD;
&#xD;
          -  Healthy volunteers who are not participating in another clinical trial or have not&#xD;
             done so in the past 2 months&#xD;
&#xD;
          -  To give blood in the four weeks before beginning of the trial&#xD;
&#xD;
        Patients with renal insufficiency or elderly healthy volunteers (Groups II, III, IV, V):&#xD;
&#xD;
          -  Previous history of alcoholism or drugs consumption&#xD;
&#xD;
          -  Important consumer of exciting drinks&#xD;
&#xD;
          -  Hypersensitivity, allergy, idiosyncrasy to medicines&#xD;
&#xD;
          -  Treatment with enzymatic inhibitors or inductors medicines&#xD;
&#xD;
          -  Administration with ASA of dosis &gt; 125 mg/day and/or NDAIs with half-life &gt; 20 hours&#xD;
             or with high antiagregant effect during the previous ten days to the inclusion&#xD;
&#xD;
          -  Chronic hepatopatology&#xD;
&#xD;
          -  bilirubin levels &gt; 1,5 mg/dl and/or increment of AST/ALT levels twice higher than&#xD;
             maximum limit of normality&#xD;
&#xD;
          -  prothrombin time 20% higher than maximun limit of normality and haemoglobine &lt; 8gr/dl&#xD;
             or albumim levels &lt;3gr/dl&#xD;
&#xD;
          -  Previous history of acute infarction of myocardium, cardiac ischemic or arrhythmia&#xD;
&#xD;
          -  Acute illness in the previous week to the participation&#xD;
&#xD;
          -  Familiar history of coagulation's disorders&#xD;
&#xD;
          -  surgery within the previous 6 months&#xD;
&#xD;
          -  Women who are pregnant or who are not using effective contra conceptive methods&#xD;
&#xD;
          -  Ethanol, cannabis, cocaine, amphetamine, benzodiazepin or opiate in urine&#xD;
&#xD;
          -  Current platelet count &lt; 75.000/mm3 or serum K &gt; 6 mEq/L&#xD;
&#xD;
          -  Any contraindication to bemiparin administration in order to authorized summary&#xD;
             product characteristics&#xD;
&#xD;
          -  Healthy volunteers who are not participating in another clinical trial or have not&#xD;
             done so in the past 2 months&#xD;
&#xD;
          -  To give blood in the four weeks before beginning of the trial&#xD;
&#xD;
          -  Subjects in haemodialysis or peritoneal dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Barbanoj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau and Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <last_update_submitted>March 17, 2011</last_update_submitted>
  <last_update_submitted_qc>March 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Deparment</name_title>
    <organization>Rovi Pharmaceuticals Laboratories</organization>
  </responsible_party>
  <keyword>renal insufficency</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bemiparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

